ExodusPoint Capital Management LP Buys New Shares in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

ExodusPoint Capital Management LP purchased a new position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 53,500 shares of the biotechnology company’s stock, valued at approximately $480,000.

Several other hedge funds have also recently made changes to their positions in the business. SBI Securities Co. Ltd. acquired a new stake in Aurinia Pharmaceuticals during the fourth quarter worth approximately $25,000. Blue Trust Inc. grew its position in shares of Aurinia Pharmaceuticals by 3,041.4% during the 4th quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company’s stock worth $57,000 after buying an additional 6,174 shares during the period. Virtu Financial LLC bought a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter valued at $96,000. Cibc World Markets Corp acquired a new position in shares of Aurinia Pharmaceuticals during the 4th quarter valued at $113,000. Finally, FMR LLC boosted its stake in Aurinia Pharmaceuticals by 44.8% during the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock worth $93,000 after acquiring an additional 3,919 shares in the last quarter. 36.83% of the stock is owned by institutional investors.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ:AUPH opened at $7.41 on Friday. Aurinia Pharmaceuticals Inc. has a twelve month low of $4.71 and a twelve month high of $10.67. The stock’s 50 day moving average is $8.01 and its 200-day moving average is $8.09. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of -49.40 and a beta of 1.20.

Insider Buying and Selling at Aurinia Pharmaceuticals

In related news, COO Matthew Maxwell Donley sold 65,902 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $527,216.00. Following the completion of the sale, the chief operating officer now owns 739,456 shares in the company, valued at approximately $5,915,648. This represents a 8.18 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Greg Keenan sold 12,239 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $97,912.00. Following the transaction, the insider now owns 161,789 shares in the company, valued at approximately $1,294,312. This trade represents a 7.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 343,898 shares of company stock worth $2,753,094. 4.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Separately, StockNews.com raised shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 27th.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.